Press Releases Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-07 EDT			5-day change	1st Jan Change
15.78 ^USD	+1.58%		-0.34%	-39.74%

04-25	Certain Restricted Stock Units of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI
04-25	Certain Options of Tourmaline Bio, Inc. are subject to a Lock-Up Agreement Ending on 25-APR-2024.	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	03-19	GL
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares	01-29	GL
Tourmaline Bio Announces Pricing of Public Offering of Common Stock	01-25	GL
Tourmaline Bio Announces Proposed Public Offering of Common Stock	01-24	GL
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)	01-08	GL
Tourmaline Bio added to the NASDAQ Biotechnology Index	12-15	GL
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board	12-14	GL
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio	23-10-17	AQ
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio	23-10-06	AQ
New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics	23-10-04	AQ
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS	23-09-28	BU
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS	23-06-24	BU
TALARIS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-06-22	AQ
TALS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Talaris Therapeutics, Inc. Is Fair to Shareholders	23-06-22	BU
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement	23-06-22	AQ
Talaris Therapeutics Announces Leadership Transition	23-05-26	AQ
Talaris Therapeutics : Costs Associated with Exit/Disposal - Form 8-K	23-04-14	PU
TALARIS THERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	23-04-14	AQ
TALARIS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-31	AQ
TALARIS THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)	23-03-10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Tourmaline Bio, Inc.

Equities

TRML

US89157D1054

Press Releases

Filters